-+ 0.00%
-+ 0.00%
-+ 0.00%

Maze Therapeutics publishes corporate presentation on genetics-driven kidney and metabolic disease pipeline

PUBT·04/22/2026 04:27:42
Listen to the news
Maze Therapeutics publishes corporate presentation on genetics-driven kidney and metabolic disease pipeline
  • Maze outlined a kidney- and metabolic-disease pipeline built around small-molecule precision medicines, led by APOL1 inhibitor MZE829 for APOL1-mediated kidney disease (AMKD).
  • Initial Phase 2 HORIZON data showed a 36% mean reduction in uACR across 12 evaluable AMKD patients at 12 weeks.
  • Non-diabetic AMKD patients posted a 49% mean uACR reduction, including a 62% mean reduction in FSGS subset.
  • Safety update showed no serious adverse events in 15 treated patients; treatment-related adverse events were mostly mild or moderate.
  • Maze projected operating capital into 2029, with additional HORIZON data targeted for late 2026 or early 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief on April 21, 2026, and is solely responsible for the information contained therein.